[HTML][HTML] Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy

D Duan - Molecular Therapy, 2018 - cell.com
Duchenne muscular dystrophy (DMD) is a lethal muscle disease caused by dystrophin gene
mutation. Conceptually, replacing the mutated gene with a normal one would cure the …

AAV-based gene therapies for the muscular dystrophies

JM Crudele, JS Chamberlain - Human molecular genetics, 2019 - academic.oup.com
Muscular dystrophy (MD) is a group of progressive genetic diseases affecting the
musculature that are characterized by inflammatory infiltrates, necrosis and connective …

Gene therapies in canine models for Duchenne muscular dystrophy

PP Nghiem, JN Kornegay - Human Genetics, 2019 - Springer
Therapies for Duchenne muscular dystrophy (DMD) must first be tested in animal models to
determine proof-of-concept, efficacy, and importantly, safety. The murine and canine models …

[HTML][HTML] The dog model in the spotlight: legacy of a trustful cooperation

I Barthélémy, C Hitte, L Tiret - Journal of neuromuscular …, 2019 - content.iospress.com
Dogs have long been used as a biomedical model system and in particular as a preclinical
proof of concept for innovative therapies before translation to humans. A recent example of …

Gene Replacement Therapy for Duchenne Muscular Dystrophy

K Hollinger, JM Crudele, JS Chamberlain - Muscle Gene Therapy, 2019 - Springer
Duchenne muscular dystrophy (DMD) is a fatal, X-linked disease caused by mutations in the
massive dystrophin gene that lead to extremely low or non-detectable levels of dystrophin …

Muscular Dystrophy

K Hollinger, JM Crudele… - Muscle Gene Therapy, 2019 - books.google.com
Duchenne muscular dystrophy (DMD) is a fatal, X-linked disease caused by mutations in the
massive dystrophin gene that lead to extremely low or non-detectable levels of dystrophin …